Phase 2 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with head and neck cancer confirmed by a tissue sample (biopsy).
- People whose cancer is locally advanced and has not spread to distant parts of the body, based on specific staging categories (confirm with trial site for exact staging details).
- People who are planned to receive radiation therapy or a combination of radiation and chemotherapy, either as the main treatment or after surgery.
- People who are willing and able to give informed consent to take part in the trial.
- People who have a general health and activity level rated as reasonably functional (on a standard scale used by doctors, confirm with trial site).
- People aged 21 years or older.
- People who speak English.
Who may not be able to join:
- People who are currently taking gabapentin or ketamine.
- People who have previously not been able to tolerate gabapentin or ketamine.
- People who are unable to receive ketamine as a nasal spray due to the shape or structure of their nasal passages.
- People who have a history of seizures or a seizure disorder.
- People who have a history of schizophrenia.
- People who have a history of increased pressure in the brain.
- People whose kidneys are not functioning well enough, based on a specific blood test result (confirm with trial site for the exact level required).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Natalie Lockney, MD, Vanderbilt-Ingram Cancer Center
Phone: 800-811-8480
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Establish the maximum tolerated dose of ketamine in combination with gabapentin (per Common Terminology Criteria for Adverse Events Criteria 4.0); Count of participants with adverse events (Common Terminology Criteria for Adverse Events Criteria 4.0)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.